CDK4 and lymphoma: Virus-positive cells also demonstrated increased sensitivities to Palbociclib compared to virus-negative BJAB cells (Fig. 7I), which was consistent with previous reports51,52 and suggested that CDK4/CDK6 may have additional functions to support the survival and proliferation of virus-transformed lymphoma cells.